New York Times examines emergence of XDR-TB in Australia, PNG

NewsGuard 100/100 Score

"Australia's first death from XDR-TB -- extensively drug-resistant tuberculosis, which is nearly incurable -- has alarmed health officials and added new heat to a debate over how to treat immigrants with dangerous diseases," the New York Times reports. "A long string of small Australian islands -- bits of what was once a land bridge -- mingle with islands belonging to Papua New Guinea, one of the world's poorest nations," the newspaper notes, adding, "One of those islands, Daru, has a major TB outbreak in its shantytowns."

"But the health system in Papua New Guinea is overwhelmed," the New York Times writes, adding, "A World Health Organization report found serious drug shortages, and Australian television showed XDR patients mingling with others in Daru Hospital tuberculosis wards, raising the risk of spreading resistant strains." The newspaper continues, "Australia, which otherwise has little tuberculosis within its borders, is still debating how to respond," noting, "Treatment for drug-resistant TB -- when it works -- can cost hundreds of thousands of dollars" (McNeil, 3/25).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicines